Prostate specific antigen changes as related to the initial prostate specific antigen: Data from the prostate, lung, colorectal and ovarian cancer screening trial

Journal of Urology

Volumn 175, Issue 4, 2006, Pages 1286-1290

  Crawford, E David ^a,h   Pinsky, Paul F ^b   Chia, David ^d   Kramer, Barnett S ^e   Fagerstrom, Richard M ^b   Andriole, Gerald ^f   Reding, Douglas ^g   Gelmann, Edward P ^c   Levin, David L ^b   Gohagan, John K ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g MARSHFIELD CLINIC   (United States)

^h UCHSC ^*  (United States)

Author keywords

Mass screening; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33644592792     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00706-8     Document Type: Article

References (20)

1. H.L. Howe, P.A. Wingo, M.J. Thun, L.A. Ries, H.M. Rosenberg, E.G. Feigal Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends J Natl Cancer Inst 93 2001 824
2. R.A. Smith, V. Cokkinides, H.J. Eyre American Cancer Society American Cancer Society guidelines for the early detection of cancer, 2003 CA Cancer J Clin 53 2003 27
3. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA) Oncology 14 2000 267 (Williston Park)
4. R. Zoorob, R. Anderson, C. Cefalu, M. Sidani Cancer screening guidelines Am Fam Physician 63 2001 1101
5. R. Harris, K.N. Lohr Screening for prostate cancer an update of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 137 2002 917
6. E.P. DeAntoni, E.D. Crawford, J.E. Oesterling, C.A. Ross, E.R. Berger, D.G. McLeod Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study Urology 48 1996 234
7. D.S. Smith, W.J. Catalona, J.D. Herschman Longitudinal screening for prostate cancer with prostate-specific antigen JAMA 276 1996 1309
8. P.C. Prorok, G.L. Andriole, R.S. Bresalier, S. Buys, D. Chia, E.D. Crawford Design of the Prostate, Lung, Colon and Ovarian (PLCO) cancer screening trial Controll Clin Trials 21 suppl. 2000 273S
9. G.L. Andriole, D.L. Levin, E.D. Crawford, E.P. Gelmann, P.F. Pinsky, D. Chia Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial findings from the initial screening round of a randomized trial J Natl Cancer Inst 97 2005 433
10. M.P. Fay Comparing several score tests for interval censored data Stat Med 18 1999 273
11. B.J.T. Morgan Analysis of Quantal Response Data 1992 Chapman and Hall London
12. C.H. Harris, B.L. Dalkin, E. Martin, P.C. Marx, F.R. Ahmann Prospective longitudinal evaluation of men with initial prostate specific antigen level of 4 ng/ml. or less J Urol 157 1997 1740
13. H.B. Carter, J.I. Epstein, D.W. Chan, J.L. Fozard, J.D. Pearson Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer JAMA 277 1997 1456
14. E.D. Crawford, E.P. DeAntoni, R. Etzioni, V.C. Schaefer, R.M. Olson, C.A. Ross Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program Urology 47 1996 863
15. J. Hugosson, G. Aus, H. Lilja, P. Lodding, C.G. Pihl, E. Pileblad Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable J Urol 169 2003 1720
16. M.J. Roobol, D.W. Roobol, F.H. Schroder Is additional testing necessary in men with prostate-specific antigen levels of 10 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343
17. S.D. Kundu, R.L. Grubb, K.A. Roehl, J.A.V. Antenor, M. Han, W.J. Catalona Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml J Urol 173 2005 1116
18. G.W. Chodak, P. Keller, H.W. Schoenberg Assesment of screening for prostate cancer using the digital rectal examination J Urol 141 1989 1136
19. W.J. Catalona, J.P. Richie, F.R. Ahmann, M.A. Hudson, P.T. Scardino, R.C. Flanigan Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men J Urol 151 1994 1283
20. W.J. Catalona, C.G. Ramos, G.F. Carvalhal, Y. Yan Lowering PSA cutoffs to enhance detection of curable prostate cancer Urology 55 2000 791